Black innovators contribution to health & wellness throughout the years
Read about the many contributions Black innovators have made throughout history and how they continue to shape scientific discoveries today.
Search
Full results from EMPERIAL exercise ability trials presented
Full results from EMPERIAL exercise ability trials presented
FDA Approves Pradaxa, Marking a Major Milestone to Reduce the Risk of Stroke in Patients with Non-Valvular Atrial Fibrillation
FDA Approves Pradaxa, Marking a Major Milestone to Reduce the Risk of Stroke in Patients with Non-Valvular Atrial Fibrillation
Results for Jardiance® (empaglifozin) | BI US
Read more about JARDIANCE, a significant reduction of risk for cardiovascular death or hospitalization for heart failure.
FDA Mini-Sentinel Assessment Reinforces Safety Data of Pradaxa® (dabigatran etexilate mesylate)
FDA Mini-Sentinel Assessment Reinforces Safety Data of Pradaxa® (dabigatran etexilate mesylate)
Ridgefield, Connecticut, home to our U.S. headquarters, is ranked #1 safest place to live
Read about what makes Ridgefield, Connecticut a great place to live, work, and make a difference in the lives of people and animals.
FDA approves Ofev® as first treatment for chronic fibrosing ILDs with a progressive phenotype
FDA approves Ofev® as first treatment for chronic fibrosing ILDs with a progressive phenotype
Breathless Ballad
Breathless Ballad
Our Responsibility
Our Responsibility
Bringing focus to unmet needs in biliary tract and pancreatic cancer with the Brightline-2 Trial
Brightline-2 clinical trial is studying our investigational MDM2-p53 antagonist for people with advanced cancer in the biliary tract or pancreatic cancer.
BI Cares: Supporting Ukraine
Our family-owned company condemns the ongoing military aggression against Ukraine, and have maintained our support for those in need by providing financial and in-kind donations through our Boehringer Ingelheim Cares Foundation.
Sant Cugat del Vallès (Barcelona)
Boehringer Ingelheim settled in Spain in 1952. For almost 70 years, t
Spesolimab prevented generalized pustular psoriasis flares in Effisayil™ 2 trial
Spesolimab prevented generalized pustular psoriasis flares in Effisayil™ 2 trial
Driving Innovation through Diversity & Inclusion
Driving innovation through diversity and inclusion. Inclusive leaders and an inclusive organisation allow diversity to flourish. Diversity is the mix. Inclusion is making the mix work.
Retinal Diseases
Retinal Diseases
Heart Diseases
Heart Diseases
Real-world data announced for adults with type 2 diabetes
Two analyses of the U.S. data from the EMPRISE real-world study show that Jardiance (empagliflozin) tablets was associated with a reduction in risk of hospitalization for heart failure compared with two other classes of glucose-lowering therapies in adult
New Analyses Showed Consistent Efficacy of OFEV® (nintedanib) Across Various Patient Populations with Idiopathic Pulmonary Fibrosis (IPF)
New Analyses Showed Consistent Efficacy of OFEV® (nintedanib) Across Various Patient Populations with Idiopathic Pulmonary Fibrosis (IPF)
More Health Overview
Working at the intersection of human and animal health, we have unique opportunities to positively impact vulnerable populations.
Recognizing Parents Supporting Other Parents
Recognizing Parents Supporting Other Parents
Fremont, California
Boehringer Ingelheim’s Fremont, California facility in the San Francisco Bay
More Potential
More Potential
Niha Agarwalla
My career challenge at Boehringer Ingelheim by Niha Agarwalla. Read it now!
Top-line Phase II Data for treatment of MASH
Boehringer Ingelheim and Zealand Pharma announced top-line Phase II data for treatment of metabolic dysfuntion-associated steatohepatitis (MASH).
Cancer
Cancer